INT206764

Context Info Confidence 0.1904229200 First Reported 2007 Last Reported 2010 Negated 0 Speculated 0 Reported most in NULL Documents 8 Total Number 9

cytoplasm (AQP4, Nqo1) cytosol (Nqo1) transport (AQP4) oxidoreductase activity (Nqo1) plasma membrane (AQP4) transmembrane transport (AQP4)

AQP4 (Homo sapiens) Nqo1 (Mus musculus)

Pain Term Frequency Confidence Heat Demyelination 16 99.46 medulla 2 95.96 corticosteroid 4 42.48 imagery 10 14.72 cerebral cortex 6 5 Spinal cord 52 5 Central nervous system 36 5 midbrain 6 5 carpal tunnel syndrome 2 5 intrathecal 36 5

Disease Term Frequency Confidence Heat Autonomic Nervous System Disease 2 97.36 Respiratory Failure 5 94.08 Channelopathies 2 91.72 Syndrome 24 87.52 Hyalinosis 3 82.88 Necrosis 6 82.48 Hyperplasia 3 82.12 Congenital Anomalies 8 79.36 Relapsing-remitting Multiple Sclerosis 2 69.72 Increased Venous Pressure Under Development 2 61.36

Sentences Mentioned In

Key:

Protein

Event

Anatomy

Negation

Speculation

Pain term

Lennon and colleagues discovered a biomarker for NMO; NMO-IgG is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which binds to aquaporin-4 (AQP4) [11], the most abundant water channel in the CNS [12-14].

AQP4 Binding (binds) of NMO-IgG

1) Confidence 0.0466765778031529 Published 2010 Journal N/A Section N/A Doc Link PMC2941752

Lennon and colleagues discovered a biomarker for NMO; NMO-IgG is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which binds to aquaporin-4 (AQP4) [11], the most abundant water channel in the CNS [12-14].

aquaporin-4 Binding (binds) of NMO-IgG

2) Confidence 0.0466765778031529 Published 2010 Journal N/A Section N/A Doc Link PMC2941752

Thus we hypothesized that AQP4 antibodies in fact characterize NMO patients.

AQP4 Binding (characterize) of NMO

3) Confidence 0.0285731317677099 Published 2007 Journal N/A Section N/A Doc Link PMC1852124

It is therefore still unclear whether antibodies to AQP4 are specific for NMO and whether testing for these antibodies may be useful for its diagnosis and its distinction from diseases with similar clinical and neuroradiological patterns, such as MS and other autoimmune diseases with involvement of the CNS.

AQP4 Binding (specific) of NMO

4) Confidence 0.0274655216036807 Published 2007 Journal N/A Section N/A Doc Link PMC1852124

The limited access of circulating IgG to the extracapillary space in the CNS would only permit interaction of NMO-IgG with AQP4 at the glia limitans of BBB: in consequence of these findings, many authors suggest the perivascular space as the primary target site of the pathogenic process.

AQP4 Binding (interaction) of NMO

5) Confidence 0.0229482138959204 Published 2010 Journal N/A Section N/A Doc Link PMC2923365

Moreover, two pathologic patterns in NMO, both of which were associated with loss of AQP4 immunoreactivity were described [39].

AQP4 Binding (associated) of NMO

6) Confidence 0.0177522037091431 Published 2010 Journal N/A Section N/A Doc Link PMC2923365

In summary, the intriguing report by Roemer and colleagues [80], describing loss of AQP4 in the absence of demyelination or necrosis suggests that binding of antibody to AQP4 may be the initial pathogenic event in NMO lesions.

AQP4 Binding (binding) of NMO

7) Confidence 0.0177522037091431 Published 2010 Journal N/A Section N/A Doc Link PMC2923365

In 70-80% of cases, neuromyelitis optica (NMO) is associated with highly specific serum auto-antibodies to aquaporin-4 (termed AQP4-Ab or NMO-IgG).

aquaporin-4 Binding (associated) of NMO

8) Confidence 0.00502201274017981 Published 2010 Journal N/A Section N/A Doc Link PMC2945323

In 70-80% of cases, neuromyelitis optica (NMO) is associated with highly specific serum auto-antibodies to aquaporin-4 (termed AQP4-Ab or NMO-IgG).

AQP4 Binding (associated) of NMO

9) Confidence 0.00502201274017981 Published 2010 Journal N/A Section N/A Doc Link PMC2945323

General Comments

This test has worked.